The SLAS Nominating Committee is pleased to announce these three SLAS Board of Directors candidates for four-year terms beginning in January 2026.
Per the Society’s policy, any SLAS member in good standing may submit a petition nominating an alternative candidate.
Formal petitions challenging a candidate may be submitted until October 6, 2025. Questions, comments and petitions should be emailed directly to SLAS CEO, Vicki Loise.
I am excited by the opportunity to serve on the SLAS Board of Directors, bringing my long-standing commitment and deep knowledge of the organization. Since SLAS’s formation in 2010, I have contributed as a conference attendee, speaker, session chair, track chair, member and chair of the Americas Scientific Programme Committee, and International Conference chair in 2020. Additionally, I have reviewed for SLAS Discovery and judged the Innovation Award, finding all roles incredibly rewarding.
I am also excited to bring my board leadership experience to this position. I have served on the ELRIG board since 2017, chairing it from 2020, which has provided me with experience in leading strategy and governance in a not-for-profit society serving the life sciences. I have stepped aside as chair of ELRIG’s strategic discussions and will be leaving the board by October 2025. During my tenure at ELRIG, I fostered positive collaboration with SLAS, chairing sessions at SLAS Europe and championing discussions about partnering for the benefit of both organizations.
Additionally, I serve on the board of OneNucleus, supporting the Cambridge, UK start-up ecosystem. This role complements SLAS, as its mission and geographical focus are distinct. In fact, connectivity to the UK life sciences ecosystem can benefit SLAS.
Finally, as VP of Assays, Profiling & Cell Sciences at AstraZeneca, I lead teams spanning Cambridge, UK, Sweden, and Boston, providing me with a network and exposure to the science in each region, and a deep understanding of scientific and strategic trends in biopharma, particularly in Europe. I am passionate about transforming research through collaboration and innovation, aligning closely with SLAS’s mission.
SLAS has greatly shaped my professional journey, and I would be honoured to support its future as a dedicated member of the board.
I am excited about the opportunity to serve and to contribute to the future success of SLAS. I’m currently a senior researcher at Karolinska Institutet and SciLifeLab in Stockholm, Sweden. I have extensive experience in leadership roles within SLAS, domain knowledge, an active network and a proven track record of serving the SLAS community.
My involvement with SLAS includes previous roles as the chair, vice-chair and member of the European Scientific Planning Committee, representative on the Knowledge and Content Dissemination Committee, General Chair of the SLAS meeting in Dublin 2022, program member of Building Biology in 3D 2021, and session chair at the SLAS Europe meeting in Barcelona 2019. I will contribute to the European planning team for the 2026 conference.
My leadership skills extend beyond SLAS into the academic screening community. I am head of the assay development and screening team at the Chemical Biology Consortium Sweden, a national infrastructure for chemical biology services in Sweden. Additionally, I am a researcher at Karolinska, with a focus on high-content screening in near-patient models. Throughout my research career, I have established close collaborations with industry, translating academic research into practical applications.
My ability to navigate and foster these collaborations underscores my long-term commitment to technology development, high-throughput screening and bridging the gap between research and application. These experiences have not only developed my organizational and leadership skills but also deepened my commitment to advancing the mission of SLAS. As a member of the Board of Directors, I will leverage my personal experience and dedication to contribute to the strategic direction and governance of our organization. I am eager to work alongside my colleagues to continue promoting SLAS.
I am an Assistant Research Scientist in the Department of Surgery at UC San Diego Health, where my laboratory pioneers patient-derived 3-D cultures and multi-cellular co-culture platforms to uncover and overcome drug resistance in cancer. Within SLAS, I have co-organized 3D modeling specialty meetings since 2021, served as associate and full track chair for two Annual Conferences, and co-chaired the successful 2025 scientific program. I also joined the SLAS Discovery editorial board as an Associate Editor and serve on the ASPC and KCDC. During my tenure with SLAS, I have championed diverse voices and emerging technologies and built content suited for academia, biotech and pharma.
As a member of the SLAS Board of Directors, I will proactively partner with fellow Board members and the CEO to advance three key priorities:
My history of collaborative program design, data-driven decision-making, and transparent communication positions me to integrate quickly into Board teamwork, challenge ideas constructively, and translate strategic vision into actionable plans. I look forward to working closely with the CEO to ensure our initiatives remain fiscally responsible, scientifically forward-looking and member-centric.
